Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 10;21(1):58.
doi: 10.1186/s12876-021-01635-6.

Evaluation of serum ATX and LPA as potential diagnostic biomarkers in patients with pancreatic cancer

Jiang Chen  1 , Hongyu Li  1 , Wenda Xu  1 , Xiaozhong Guo  2
Affiliations

Evaluation of serum ATX and LPA as potential diagnostic biomarkers in patients with pancreatic cancer

Jiang Chen et al. BMC Gastroenterol. .

Abstract

Background: Pancreatic cancer (PC) is a devastating disease that has a poor prognosis and a total 5-year survival rate of around 5%. The poor prognosis of PC is due in part to a lack of suitable biomarkers that can allow early diagnosis. The lysophospholipase autotaxin (ATX) and its product lysophosphatidic acid (LPA) play an essential role in disease progression in PC patients and are associated with increased morbidity in several types of cancer. In this study, we evaluated both the potential role of serum LPA and ATX as diagnostic markers in PC and their prognostic value for PC either alone or in combination with CA19-9.

Methods: ATX, LPA and CA19-9 levels were evaluated using ELISA of serum obtained from PC patients (n = 114) healthy volunteers (HVs: n = 120) and patients with benign pancreatic diseases (BPDs: n = 94).

Results: Serum levels of ATX, LPA and CA19-9 in PC patients were substantially higher than that for BPD patients or HVs (p < 0.001). The sensitivity of LPA in early phase PC was 91.74% and the specificity of ATX was 80%. The levels of ATX, LPA and CA19-9 were all substantially higher for early stage PC patients compared to levels in serum from BPD patients and HVs. The diagnostic efficacy of CA19-9 for PC was significantly enhanced by the addition of ATX and LPA (p = 0.0012).

Conclusion: Measurement of LPA and ATX levels together with CA19-9 levels can be used for early detection of PC and diagnosis of PC in general.

Keywords: Autotaxin; Biological markers; Diagnosis; Lysophospholipids; Pancreatic neoplasms.

PubMed Disclaimer

Conflict of interest statement

There were no any financial and non-financial competing interests in this article.

Figures

Fig. 1
Fig. 1
Receiver Operating Characteristic (ROC) curve analysis of serum ATX, LPA, and CA19-9 levels for prediction of overall, early tumor stage, and late tumor stage PC relative to levels in BPD patients and HVs
Fig. 2
Fig. 2
Receiver Operating Characteristic (ROC) curve comparing ATX, LPA, and CA19-9 levels for early detection of PC relative to levels in BPD patients and HVs. The Areas Under the ROC Curve (AUROC) were 0.836 for CA19-9, 0.824, for ATX, and 0.908 for LPA
See this image and copyright information in PMC

References

    1. Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, Hruban RH. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63:318–348. doi: 10.3322/caac.21190. - DOI - PMC - PubMed
    1. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605–1617. doi: 10.1056/NEJMra0901557. - DOI - PubMed
    1. Poruk KE, Firpo MA, Adler DG, Mulvihill SJ. Screening for pancreatic cancer: why, how, and who? Ann Surg. 2012;257(1):17–26. doi: 10.1097/SLA.0b013e31825ffbfb. - DOI - PMC - PubMed
    1. Duraker N, Hot S, Polat Y, Hobek A, Gencler N, Urhan N. CEA, CA 19–9, and CA125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol. 2007;95(2):142–147. doi: 10.1002/jso.20604. - DOI - PubMed
    1. Harsha HC, Kandasamy K, Ranganathan P, Rani S, Ramabadran S, Gollapudi S, Balakrishnan L, Dwivedi SB, Telikicherla D, Selvan LD, Goel R, Mathivanan S, Marimuthu A, Kashyap M, Vizza RF, Mayer RJ, Decaprio JA, Srivastava S, Hanash SM, Hruban RH, Pandey A. A compendium of potential biomarkers of pancreatic cancer. PLoS Med. 2009;6(4):e1000046. doi: 10.1371/journal.pmed.1000046. - DOI - PMC - PubMed